Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06365905 · ClinicalTrials.gov registry record

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

A clinical trial of Endometrial Carcinoma, sponsored by Mayo Clinic.

Recruiting
Registry status
300
Enrollment target
3
Study locations

NCT06365905: Recruiting study of Endometrial Carcinoma, sponsored by Mayo Clinic.

NCT06365905 is a study of Endometrial Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 300 participants, below the 380-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (21% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06365905, a study of Endometrial Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
300 participants
Enrollment target
3
Study locations

Study Summary

This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions.

Primary Outcome

Two static TVUS images (one longitudinal, one transversal) will be independently validated and compared to results of endometrial sampling. Outcomes from these will be compared with predictions made by the AI models for accuracy of assessing premalignant/malignant disease.

Conditions Studied

Interventions

  • OTHER Non-Interventional Study

Study Locations (3)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Florida

  • Mayo Clinic in Florida - Jacksonville

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2024-03-27
Est. Completion 2027-06-30
Mayo Clinic

2,844 total trials

What NCT06365905 shows while recruiting

NCT06365905 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 380-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (21% lower).

The record links to 1 condition, with Endometrial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT06365905 reports a single indexed study location in Arizona, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT06365905 about?

NCT06365905 is a clinical study titled "Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding". This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions.

What is the current status of trial NCT06365905?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-03-27. Estimated completion is 2027-06-30.

What conditions does trial NCT06365905 study?

This clinical trial studies the following conditions: Endometrial Carcinoma.

What interventions are being tested in trial NCT06365905?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT06365905?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06365905 being conducted?

This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Endometrial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06365905's enrollment target sits among peer trials

300 5th of 27 higher than 23 of 27 other Endometrial Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometrial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06365905, the US trial registry maintained by the National Library of Medicine. NCT06365905 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.